Related Experiment Video
Updated: Jun 22, 2026
Following in Real Time the Impact of Pneumococcal Virulence Factors in an Acute Mouse Pneumonia Model Using Bioluminescent Bacteria
Published on: February 23, 2014
Efficacy of pneumococcal vaccination in children younger than 24 months: a meta-analysis
Maria Pavia1, Aida Bianco, Carmelo G A Nobile
1Department of Hygiene, Medical School, University of Catanzaro Magna Graecia, Catanzaro, Italy.
Insights
Pneumococcal conjugate vaccines significantly prevent invasive pneumococcal disease in infants. While less effective against otitis media and pneumonia, their impact on infant health remains substantial, especially in developing nations.
Area of Science:
- Pediatric Infectious Diseases
- Vaccinology
- Public Health
Background:
- Pneumococcal conjugate vaccines (PCVs) have been developed to prevent invasive diseases and mucosal infections caused by Streptococcus pneumoniae.
- The efficacy of these vaccines in preventing serious infant infections is a critical public health concern.
Purpose of the Study:
- To conduct a meta-analysis of published clinical trials on pneumococcal conjugate vaccine efficacy.
- To determine the vaccine's effectiveness in reducing invasive pneumococcal disease, pneumonia, and acute otitis media in infants under 24 months.
Main Methods:
- Systematic literature search of controlled clinical trials comparing PCV to placebo or control vaccines.
- Inclusion criteria focused on healthy infants younger than 24 months and outcomes of invasive disease, pneumonia, and acute otitis media.
- Standardized protocol used for data extraction and efficacy analysis.
Main Results:
- PCV demonstrated high efficacy (89%) in preventing invasive pneumococcal disease caused by vaccine serotypes.
- Efficacy against acute otitis media was moderate (55-57% for vaccine serotypes).
- Efficacy was lower for clinical pneumonia (6-7%) but higher for radiograph-confirmed pneumonia (29-32%).
Conclusions:
- Pneumococcal conjugate vaccine is highly effective against invasive pneumococcal disease.
- While less impactful on otitis media and pneumonia, the vaccine's efficacy holds significant potential public health benefits for infants globally.
- Further research may explore strategies to enhance protection against mucosal infections.
Context:
Pneumococcal conjugate bacterial vaccines that are able to prevent invasive disease and mucosal infections have been developed.
Objective:
A meta-analysis of published data from trials on pneumococcal conjugate vaccine was performed to determine the efficacy in reducing the incidence of invasive disease caused by Streptococcus pneumoniae, pneumonia, and acute otitis media in healthy infants younger than 24 months.
Methods:
A systematic search of the literature was conducted. Controlled clinical trials had to compare the protective efficacy of the pneumococcal conjugate vaccine in reducing the incidence of invasive disease caused by S pneumoniae, pneumonia, and acute otitis media in healthy infants with placebo or control vaccines. Information was extracted by using a standardized protocol.
Results:
The efficacy of pneumococcal conjugate vaccine in the reduction of invasive pneumococcal disease was 89% involving vaccine serotypes in both the intention-to-treat and per-protocol analyses and ranged from 63% to 74% for all serotypes. The efficacy to prevent acute otitis media sustained by vaccine serotypes was 55% in the intention-to-treat and 57% in the per-protocol analyses, whereas it was 29% to prevent otitis involving all serotypes in the per-protocol analysis. Finally, in the intention-to-treat and per-protocol analyses, the efficacy to prevent clinical pneumonia was 6% and 7%, respectively, whereas for the prevention of radiograph-confirmed pneumonia it was 29% and 32%, respectively.
Conclusions:
The pneumococcal conjugate vaccine produces a significant effect regarding prevention of invasive pneumococcal disease. Results on prevention of otitis or pneumonia have been less striking, but considering the high burden of these diseases in infants, even a low efficacy has potential for tremendous impact on the health of infants in developing and industrialized countries.
Related Concept Videos
01:30Pneumonia V: Nursing management and Prevention
The nurse must practice strict medical asepsis and adhere to infection control guidelines to minimize healthcare-associated infections.
Enhance airway patency
Position the patient correctly to facilitate drainage of the affected lung segments. Manual or mechanical percussion and vibration can also be employed.
01:26Pharmacokinetics in Pediatric Patients: Drug Excretion
01:23Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption
01:24Pharmacokinetics in Pediatric Patients: Drug Metabolism
01:29Respiratory Syncytial Virus Disease
01:30Pneumonia III: Complications and Assessment